Make your one-time, tribute, or recurring online gift to support brain tumour patient programs and research today:
The information on this web site is subject to change. The viewer is advised that information obtained from a physician should be considered more up to date and accurate than the information on the website and that this website does not and cannot purport to address facts and circumstances particular to any patient. This is something that can only be done by the patient's physician.
Brain Tumour Foundation of Canada does not endorse or recommend any particular form or forms of therapy, regimen, or behaviour discussed on this web site.
Links to sites listed here are not under the control of Brain Tumour Foundation of Canada. This means that Brain Tumour Foundation of Canada can make no representation concerning the content of these sites to you, nor can the fact that Brain Tumour Foundation of Canada has given you this link serve as an endorsement by Brain Tumour Foundation of Canada. Brain Tumour Foundation of Canada provides links only as a convenience to you; this is to inform you that Brain Tumour Foundation of Canada has not verified any information or tested any software found on these sites and therefore cannot make any representations regarding the quality, safety or suitability of any information/software found there.
New research about the brain tumour treatment Bevacizumab (Avastin®) was released at the recent American Society of Clinical Oncology (ASCO) 2013 Annual Meeting. Results were presented from two recent clinical trials focused on the treatment. Because Avastin is one of the few new treatments that have been offered to brain tumour patients in recent years, Brain Tumour Foundation of Canada was eagerly awaiting these results.Learn more
When Carol Kovosi talks about......Learn more
In 2011 Micah Nepon’s brother Jonah was diagnosed......Learn more